Analytical performance of three whole blood point-of-care lactate devices compared to plasma lactate comparison methods and a flow-injection mass spectrometry method.
OBJECTIVE
Point of care (POC) whole blood lactate testing may facilitate rapid detection of sepsis. We evaluated three POC methods against both plasma lactate comparison methods and a flow-injection mass spectrometric (MS) method.


METHODS
Nova StatStrip, Abbott i-STAT CG4+ and Radiometer ABL90 POC lactate methods were evaluated against the mean of Cobas Integra 400 and Vitros 350 plasma lactate. POC methods were also compared to a flow-injection mass spectrometric assay measuring lactate in ZnSO4-precipitated whole blood extracts. Intra- and inter-assay precision was determined using quality control material. Method comparison included specimens from normal donors at rest, after exertion, and after spiking with lactic acid.


RESULTS
Intra- and inter-assay coefficient of variation was <5% for i-STAT and ABL90; but ranged from 3.1-8.2% on two StatStrip meters. Mean (±SD) bias between POC and plasma lactate ranged from -0.2±0.9 (i-STAT and ABL90) to -0.4±1.2 (StatStrip) mmol/L. At concentrations >6mmol/L, all POC methods showed proportional negative bias compared to plasma methods; but this bias was not observed when compared to the MS method. Despite proportional negative bias, all POC methods demonstrated acceptable concordance (94-100%) with plasma lactate within the reference interval (<2.3mmol/L) and >4mmol/L, commonly used clinical cut-offs for detection of sepsis.


CONCLUSIONS
POC lactate methods demonstrate acceptable concordance with plasma lactate across commonly used clinical cut-offs for detection of sepsis. Due to systematic negative bias at higher lactate concentrations, POC and plasma lactate should not be used interchangeably to monitor patients with elevated lactate concentrations.
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, United States.
Nicole V
NV
Tolan
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States.
Amy M
AM
Wockenfus
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States.
Christopher D
CD
Koch
Department of Pediatrics, St. Louis Children's Hospital and Washington University School of Medicine, St. Louis, MO 63110, United States; TPMG Regional Laboratories, Richmond, CA 94804, United States.
Bridgit O
BO
Crews
Department of Pediatrics, St. Louis Children's Hospital and Washington University School of Medicine, St. Louis, MO 63110, United States.
Dennis J
DJ
Dietzen
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States. Electronic address: Karon.bradley@mayo.edu.
Brad S
BS
Karon
D001774:Blood Chemical Analysis / Q000295:instrumentation* / Q000379:methods / Q000592:standards; D006801:Humans; D019344:Lactic Acid / Q000097:blood*; D019095:Point-of-Care Systems; D012015:Reference Standards; D018805:Sepsis / Q000097:blood / Q000175:diagnosis
D019344:Lactic Acid
Critical care testing; Lactate; Mass spectrometry; Method comparison; Point of care